全文获取类型
收费全文 | 447篇 |
免费 | 19篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 55篇 |
妇产科学 | 4篇 |
基础医学 | 35篇 |
口腔科学 | 8篇 |
临床医学 | 27篇 |
内科学 | 93篇 |
皮肤病学 | 5篇 |
神经病学 | 29篇 |
特种医学 | 152篇 |
外科学 | 21篇 |
综合类 | 6篇 |
预防医学 | 7篇 |
眼科学 | 3篇 |
药学 | 16篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 1篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2015年 | 4篇 |
2014年 | 2篇 |
2013年 | 7篇 |
2012年 | 3篇 |
2011年 | 5篇 |
2010年 | 15篇 |
2009年 | 8篇 |
2008年 | 5篇 |
2007年 | 10篇 |
2006年 | 10篇 |
2005年 | 4篇 |
2004年 | 6篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 7篇 |
2000年 | 3篇 |
1999年 | 8篇 |
1998年 | 31篇 |
1997年 | 25篇 |
1996年 | 28篇 |
1995年 | 28篇 |
1994年 | 16篇 |
1993年 | 20篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 9篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 13篇 |
1986年 | 12篇 |
1985年 | 20篇 |
1984年 | 11篇 |
1983年 | 13篇 |
1982年 | 22篇 |
1981年 | 9篇 |
1980年 | 14篇 |
1979年 | 1篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 12篇 |
1975年 | 6篇 |
1974年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有473条查询结果,搜索用时 0 毫秒
61.
Stephens RW; Golder JP; Fayle DR; Hume DA; Hapel AJ; Allan W; Fordham CJ; Doe WF 《Blood》1985,66(2):333-337
Adherent monolayer cultures of human blood monocytes, peritoneal macrophages, bone marrow macrophages, and colonic mucosa macrophages were examined for their ability to produce and secrete minactivin, a specific inactivator of urokinase-type plasminogen activator. All except colonic mucosa macrophages produced and secreted appreciable amounts of minactivin, but only blood monocytes were stimulated by muramyl dipeptide (adjuvant peptide) to increase production. The minactivin from each of these populations could be shown to preferentially inhibit urokinase-type plasminogen activator and not trypsin, plasmin, or "tissue"-type plasminogen activator (HPA66). A plasminogen-activating enzyme present in monocyte cultures appeared unaffected by the presence of minactivin and could be shown to be regulated independently by dexamethasone. 相似文献
62.
Sepsis is a common cause of morbidity and mortality. Neutrophils are the major defense against bacterial invasion, and granulocyte colony- stimulating factor (G-CSF) augments both neutrophil number and function. In our study, 160 rabbits were inoculated transtracheally with 0.5 mL of a solution containing 10(4) colony forming units per milliliter of Pasteurella multocida. Twenty-four hours later, chest x- rays and quantitative blood cultures demonstrated pneumonia and bacteremia. Therapy was then begun with penicillin G and either recombinant human G-CSF (rG-CSF; 5 to 8 micrograms/kg subcutaneously) or placebo every day for 5 days. Arterial blood gases and 23 other parameters of organ function were performed before inoculation and serially thereafter. All rabbits underwent histologic examination of organs at the time of septic death or when sacrificed on day 6. A total of 149 rabbits survived long enough to initiate therapy. A significant increase in leukocytes by day 4 was found in the rG-CSF-treated group. There was a trend towards improved survival in the rG-CSF group (77% v 67%; P = .13, n = 149). Analysis of pretreatment variables revealed sepsis-induced leukopenia (< or = 2,800/microL) as the only predictor of significantly improved survival with rG-CSF treatment (57% v 39%; P = .04, n = 73). The majority of the survival benefit occurred within the first 24 hours of treatment. This was before the time that a significant difference in mean white blood cell (WBC) count was observed between the study groups, making intravascular leukocytosis an unlikely explanation for the survival advantage in the rG-CSF group. No significant difference in laboratory variables reflecting organ function was demonstrated between the groups. Histologic grading of inflammation (0, normal, to 6, necrosis) in seven organs revealed that the surviving rabbits had mild but statistically significant increased inflammation in the liver, spleen, and noninoculated lung in the rG-CSF versus placebo groups (liver: 2.6 v 1.5, P < or = .0001; spleen: 3.2 v 2.3, P < or = .0001; and noninoculated lung: 2.9 v 2.5, P = .04). Administration of rG-CSF, in addition to penicillin G, in immune competent rabbits with gram-negative sepsis complicated by leukopenia significantly improved survival over antibiotics alone. The administration of rG-CSF in early sepsis for a short therapeutic duration was not associated with any clinically evident toxicity. Clinical trials using rG-CSF in septic patients with leukopenia are indicated. 相似文献
63.
CL Martyn-Simmons L Green G Ash RW Groves CH Smith JNWN Barker 《Journal of the European Academy of Dermatology and Venereology》2009,23(12):1394-1397
Background Targeted biologic therapies have made a significant impact on the treatment for moderate to severe psoriasis. In the United Kingdom, the National Institute for Health and Clinical Excellence recommends etanercept, a human recombinant tumour necrosis factor (TNF) receptor fusion protein, for moderate to severe psoriasis patients who have failed conventional therapies. There is, however, no data available on the role of other TNF antagonists for patients who have failed etanercept. Adalimumab, a fully human, anti-TNF monoclonal antibody, is approved for treatment of moderate to severe psoriasis.
Objectives To assess the efficacy and safety of adalimumab (40 mg weekly) in psoriasis patients who were non-responders to high-dosage etanercept (50 mg twice weekly).
Methods All patients attending a tertiary referral service for severe psoriasis who were non-responders to high-dosage etanercept [i.e. failed to achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) after 12 weeks of treatment] were considered for open-label adalimumab therapy for 12 weeks. Details on clinical course, PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8, and 12.
Results Four of five patients in this study had reached at least PASI 50 by week 12. Of these, two patients achieved a 75% improvement in PASI (PASI 75). No serious adverse events were reported.
Conclusions Initial data from this open-label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe psoriasis who had failed to respond to at least 3 months of high-dosage etanercept. 相似文献
Objectives To assess the efficacy and safety of adalimumab (40 mg weekly) in psoriasis patients who were non-responders to high-dosage etanercept (50 mg twice weekly).
Methods All patients attending a tertiary referral service for severe psoriasis who were non-responders to high-dosage etanercept [i.e. failed to achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) after 12 weeks of treatment] were considered for open-label adalimumab therapy for 12 weeks. Details on clinical course, PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8, and 12.
Results Four of five patients in this study had reached at least PASI 50 by week 12. Of these, two patients achieved a 75% improvement in PASI (PASI 75). No serious adverse events were reported.
Conclusions Initial data from this open-label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe psoriasis who had failed to respond to at least 3 months of high-dosage etanercept. 相似文献
64.
65.
From 1985-1987, a total of 34 couples undergoing superovulation for a
single in-vitro fertilization (IVF) cycle with clomiphene citrate and
purified follicle stimulating hormone (FSH) or human menopausal
gonadotrophin (HMG) were randomly allocated doses of intra-nasal buserelin
to induce an endogenous gonadotrophin surge, prior to oocyte collection.
The doses ranged from a single 25 microg dose to 100 microg every 4 h for
20 h. In three cycles the treatment was abandoned because of a poor ovarian
response. In the remaining 31 cycles buserelin was given to induce the
endogenous gonadotrophin surge, but there was evidence of premature
luteinization in eight cycles and a premature gonadotrophin surge in four
cycles. Although a single dose as low as 40 microg induced a surge and
resulted in a pregnancy, a single dose of 50 microg proved the most
effective minimal dose consistently to induce a gonadotrophin surge and
oocyte maturation. Recent reports using gonadotrophin-releasing hormone
(GnRH) analogues to induce a gonadotrophin surge has prompted publication
of this previously unpublished data.
相似文献
66.
67.
1. This is a review of the literature on the subject of the effects of cholinesters and their agonists on sensory nerve endings. 2. The present-day view is that acetylcholine (ACh) has an excitatory action on some cutaneous receptors. Responses appear to be limited to receptors served by small myelinated and un-myelinated axons where responsiveness is multimodal; that is, the receptors are activated by noxious thermal and mechanical stimulation. 3. The possible role played by acetylcholine in sensory transduction processes is discussed, as are other explanations for the presence of nicotinic cholinergic receptors on the terminals of cutaneous receptors. 4. The excitatory action of ACh and succinylcholine (SCh) on muscle spindles is described. Two possible mechanisms are considered: a direct depolarizing action on the nerve terminals and indirect excitation, brought about by a contracture of the intrafusal fibres on which the sensory endings lie. 5. The technique of using SCh in combination with fusimotor stimulation is described. This has provided new information about the internal workings of muscle spindles. Brief mention is also made of the action of SCh on tendon organs and joint receptors. 6. It is concluded that a direct action by cholinesters is restricted to receptors served by small axons with multimodal functions. The precise role of such an action remains the subject of speculation. Possible clinical significance is discussed. 相似文献
68.
69.
70.
Emergency room radiography of asthma: an efficacy study 总被引:2,自引:0,他引:2